Plasma Biomarkers of Alzheimer’s Pathology Identify Prodromal Dementia with Lewy bodies
Objective: To determine whether plasma biomarkers of Alzheimer’s disease (AD) pathology can predict phenoconversion from idiopathic/isolated REM sleep behavior disorder (iRBD) to dementia with Lewy…Common Genetic Variation Associated with Parkinson’s Disease Biological Measures
Objective: To identify common genetic variants associated with biological measures that have been implicated in Parkinson’s disease and related synucleinopathies. Background: Alpha synucleinopathies, mainly including…Sex Differences for Regional Lewy Body Pathology in Pathologically-Defined Lewy Body Dementia
Objective: To investigate sex differences for regional Lewy body (LB) pathology burden, and regional LB pathology association with clinical diagnosis across people with a high…Longitudinal Gait Speed Analysis at Prodromal and Early Stage of Parkinson’s Disease
Objective: We aimed at exploring gait speed (GS) as a potential biomarker of disease evolution in early stages of PD with three objectives. 1- To…Early Dementia with Lewy Bodies and Parkinson’s Disease with RBD: two faces of the same coin?
Objective: To describe clinical and imaging differences in de novo PD with and without REM sleep Behaviour Disorder (dnPDRBD – de novo PD) and de…Clinical Utility of Synuclein Skin Biopsy in the Initial Diagnosis and Evaluation of Parkinsonian Disorders
Objective: To determine the clinical utility of phosphorylated alpha-synuclein (P-SYN) within skin biopsies in diagnostic and management decisions. Background: The initial diagnosis of Parkinson’s Disease…Prevalence of Non-Motor Symptoms in Patients with Parkinson Disease in a Tertiary Hospital in Santiago, Chile.
Objective: Objective:Determine the prevalence of NMS in patients with Parkinson disease attending the Hospital San Juan de Dios Neurology Clinic. Background: Background:Parkinson disease (PD) is…Transferrin as a possible CSF biomarker in neurodegenerative proteinopathies
Objective: The aim of this study was to determine whether cerebrospinal fluid (CSF) levels of transferrin differ between patients with Parkinson´s disease (PD), multiple system…Exosomal α-synuclein in Multiple system atrophy and parkinson’s disease cause distinct synucleinopathies
Objective: In this study, we investigated the differences in exosomal α-syn between MSA and PD patients. Background: Parkinson's disease (PD) and multiple system atrophy (MSA)…An Analysis of Subgroups of Multiple System Atrophy Patients from Ampreloxetine Phase 3 Trials
Objective: To present results in the subset of patients with multiple system atrophy (MSA) and relevant MSA subgroups from two ampreloxetine phase 3 trials for…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 18
- Next Page »